Search company, investor...

Cytheris

cytheris.com

Founded Year

1999

Stage

Series D | Alive

Total Raised

$15M

Last Raised

$15M | 12 yrs ago

About Cytheris

Cytheris is dedicated to the development of growth factors able to enhance, drive and restore immune system functions. The company is particularly interested in a recombinant human interleukin-7 for immune reconstitution of immuno-depressed patients. Cytheris is a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation

Headquarters Location

175 rue Jean-Jacques Rousseau

92130,

France

Missing: Cytheris's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Cytheris's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Cytheris

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cytheris is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Cytheris Patents

Cytheris has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/24/2011

4/10/2012

Clusters of differentiation, Transcription factors, Interleukins, Immunology, Immune system

Grant

Application Date

8/24/2011

Grant Date

4/10/2012

Title

Related Topics

Clusters of differentiation, Transcription factors, Interleukins, Immunology, Immune system

Status

Grant

Latest Cytheris News

Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Pipeline Review 2016 Featuring Cytheris, Genexine, GlaxoSmithKline, OSE Immunotherapeutics & Pfizer - Research and Markets

Aug 29, 2016

Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Pipeline Review 2016 Featuring Cytheris, Genexine, GlaxoSmithKline, OSE Immunotherapeutics & Pfizer - Research and Markets August 29, 2016 02:29 PM Eastern Daylight Time DUBLIN--( BUSINESS WIRE )--Research and Markets has announced the addition of the "Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Pipeline Review, H1 2016" report to their offering. 'Interleukin 7 Receptor Subunit Alpha - Pipeline Review, H1 2016'; Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by Companies and remaining by the Universities Institutes. Furthermore, the author says; Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Interleukin-7 receptor is a protein found on the surface of cells. It is a receptor for interleukin-7. It acts as a receptor for thymic stromal lymphopoietin (TSLP). It plays an important role in T-cell acute lymphoblastic leukemia, multiple sclerosis, rheumatoid arthritis and juvenile idiopathic arthritis. The report 'Interleukin 7 Receptor Subunit Alpha - Pipeline Review, H1 2016' outlays comprehensive information on the Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively. Key Topics Covered: Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Overview Therapeutics Development Pipeline Products for Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Overview Pipeline Products for Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Comparative Analysis Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Therapeutics under Development by Companies Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) - Therapeutics under Investigation by Universities/Institutes Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Products Glance Late Stage Products

Cytheris Frequently Asked Questions (FAQ)

  • When was Cytheris founded?

    Cytheris was founded in 1999.

  • What is Cytheris's latest funding round?

    Cytheris's latest funding round is Series D.

  • How much did Cytheris raise?

    Cytheris raised a total of $15M.

  • Who are the investors of Cytheris?

    Investors of Cytheris include Forbion Capital Partners, Omnes Capital, Bioam Gestion, Innovation Capital, Caisse de depot et placement du Quebec and 7 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.